[go: up one dir, main page]

WO2001074390A3 - The use of a calcium channel blocker for treating renal disorders - Google Patents

The use of a calcium channel blocker for treating renal disorders Download PDF

Info

Publication number
WO2001074390A3
WO2001074390A3 PCT/IB2001/000518 IB0100518W WO0174390A3 WO 2001074390 A3 WO2001074390 A3 WO 2001074390A3 IB 0100518 W IB0100518 W IB 0100518W WO 0174390 A3 WO0174390 A3 WO 0174390A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
channel blocker
renal disorders
treating renal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000518
Other languages
French (fr)
Other versions
WO2001074390A2 (en
Inventor
Adrian Paul Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Ltd Great Britain, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to EP01914134A priority Critical patent/EP1284719A2/en
Priority to MXPA02009819A priority patent/MXPA02009819A/en
Priority to AU2001239510A priority patent/AU2001239510A1/en
Priority to BR0109783-0A priority patent/BR0109783A/en
Priority to CA002403950A priority patent/CA2403950A1/en
Priority to JP2001572132A priority patent/JP2003528927A/en
Publication of WO2001074390A2 publication Critical patent/WO2001074390A2/en
Publication of WO2001074390A3 publication Critical patent/WO2001074390A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention described herein relates to the use of calcium channel blockers such as amlodipine in the treatment of renal disease in normotensive animals. Also described are new unit doses of amlodipine suitable for the treatment of renal disease in normotensive cats.
PCT/IB2001/000518 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders Ceased WO2001074390A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01914134A EP1284719A2 (en) 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders
MXPA02009819A MXPA02009819A (en) 2000-04-04 2001-03-28 Treatment of renal disorders.
AU2001239510A AU2001239510A1 (en) 2000-04-04 2001-03-28 Treatment of renal disorders
BR0109783-0A BR0109783A (en) 2000-04-04 2001-03-28 Treatment of kidney disease
CA002403950A CA2403950A1 (en) 2000-04-04 2001-03-28 Treatment of renal disorders
JP2001572132A JP2003528927A (en) 2000-04-04 2001-03-28 Treatment of renal dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0008332.9 2000-04-04
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (2)

Publication Number Publication Date
WO2001074390A2 WO2001074390A2 (en) 2001-10-11
WO2001074390A3 true WO2001074390A3 (en) 2002-05-30

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000518 Ceased WO2001074390A2 (en) 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders

Country Status (12)

Country Link
EP (1) EP1284719A2 (en)
JP (1) JP2003528927A (en)
AR (1) AR027763A1 (en)
AU (1) AU2001239510A1 (en)
BR (1) BR0109783A (en)
CA (1) CA2403950A1 (en)
GB (1) GB0008332D0 (en)
MX (1) MXPA02009819A (en)
PA (1) PA8514601A1 (en)
PE (1) PE20011163A1 (en)
TN (1) TNSN01051A1 (en)
WO (1) WO2001074390A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001294354A1 (en) * 2000-12-29 2002-07-16 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
SI1443917T1 (en) * 2001-11-07 2006-06-30 Synthon Bv Tamsulosin tablets
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
CO5400144A1 (en) * 2002-03-11 2004-05-31 Novartis Ag ORGANIC COMPOUNDS
US7423009B2 (en) 2002-09-30 2008-09-09 Kowa Company, Ltd. Method for treatment of kidney diseases
BRPI0406987A (en) 2003-01-31 2006-01-10 Sankyo Co Medicament for the prevention and / or treatment of atherosclerosis, medicaments for inhibiting vascular smooth muscle cell proliferation, neointimal formation of blood vessels and vascular remodeling, medicament for the prevention of restenosis following percutaneous coronary intervention, and, medicines for the prophylaxis and / or treatment of hypertension or diseases caused by hypertension or diseases caused by hypertension, heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, kidney diseases, diabetic nephropathy, glomerulonephritis, nephrosclerosis, cerebrovascular diseases, cerebral infarction, and cerebral hemorrhage
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
MX2007011119A (en) 2005-03-15 2007-11-14 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril.
RU2398447C2 (en) * 2005-04-29 2010-09-10 Хилл'С Пет Ньютришн, Инк. Methods for prolongation of cats' lives
KR20180123021A (en) * 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 Medicines for the treatment of kidney disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290211A1 (en) * 1987-05-02 1988-11-09 Pfizer Limited Dihydropyridines
EP0459666A2 (en) * 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290211A1 (en) * 1987-05-02 1988-11-09 Pfizer Limited Dihydropyridines
EP0459666A2 (en) * 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PARFITT K.: "Martindale -The complete drug reference", 1999, PHARMACEUTICAL PRESS, LONDON, UK, XP002184526 *
RAMAN G VENKAT ET AL: "Renal effects of amlodipine in normotensive renal transplant recipients", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 14, no. 2, 1999, pages 384 - 388, XP001041763, ISSN: 0931-0509 *
RAMAN G.V. ET AL: "Modifying effects of amlidipine on cyclosporin A-induced changes in renal function in patients with psoriasis", JOURNAL OF HYPERTENSION, vol. 16, no. suppl. 4, 1998, pages S39 - S41, XP001041741 *
SNYDER P.S. ET AL.: "Evaluation of the antihypertensive agent amlodipine besylate innormotensive cats and a cat with systemic hypertension.", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 8, 1994, pages 147, XP001042122 *
SNYDER P.S.: "Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension", J. VET. INTERN. MED., vol. 12, 1998, pages 157 - 162, XP001041936 *
TOBLLI JORGE EDUARDO ET AL: "Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats.", HYPERTENSION (BALTIMORE), vol. 34, no. 4 PART 2, October 1999 (1999-10-01), pages 854 - 858, XP001041746, ISSN: 0194-911X *

Also Published As

Publication number Publication date
PE20011163A1 (en) 2001-11-12
TNSN01051A1 (en) 2005-11-10
CA2403950A1 (en) 2001-10-11
JP2003528927A (en) 2003-09-30
MXPA02009819A (en) 2003-03-27
AU2001239510A1 (en) 2001-10-15
PA8514601A1 (en) 2002-08-26
GB0008332D0 (en) 2000-05-24
EP1284719A2 (en) 2003-02-26
BR0109783A (en) 2003-01-21
AR027763A1 (en) 2003-04-09
WO2001074390A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU2002348175A8 (en) Improved dept collection practices
EG22308A (en) Tobacco treatment
AU2001227837A1 (en) Novel treatment for eye disease
EE200100293A (en) Controlled release dosage form containing GnRH-II
WO2001074390A3 (en) The use of a calcium channel blocker for treating renal disorders
GB0122729D0 (en) Improved waste treatment
AU142870S (en) Hedge trimmer
EG25829A (en) Novel treatment
DE60332663D1 (en) CCR1 receptor antagonists for treatment, among others. Demyelinating inflammatory diseases
EP1433400A4 (en) Automatic shampoo machine
HUP0401805A3 (en) Compounds suitable for treating pulmonary diseases
AU4154402A (en) Herbal pharmaceutical compositions for treating immunological disorders
GB0005863D0 (en) Hedge cutter
GB2366831B (en) Water Butts
AU2002212895A1 (en) N-type calcium channel antagonists for the treatment of pain
AU751887B2 (en) Guide bar including stump treatment
MXPA03001472A (en) Compounds for the treatment of addictive disorders.
GB2392838B (en) Calcium L-threonate for preventing or treating cartilage related diseases
MXPA02003976A (en) Sustained-release formulations for treating cns-mediated disorders.
IL154202A0 (en) Pharmaceutical compositions for treating anorectal disorders
ES1045858Y (en) OLIVES TREATMENT MACHINE.
GB0029125D0 (en) Novel treatment
IL159333A0 (en) Plant treatment composition
MXPA03001493A (en) Pseudomycins useful against plant diseases.
AU2002212896A1 (en) N-type calcium channel antagonists for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001914134

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2403950

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572132

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009819

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001914134

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001914134

Country of ref document: EP